Innovative Proteomics Nomic Bio’s proprietary nELISA technology enables scalable and cost-effective protein measurement, positioning the company as a leader in accessible proteomics solutions, ideal for pharmaceutical and biotech firms seeking to accelerate drug discovery and biomarker development.

Growth Through Funding With recent Series B funding of 42 million dollars and prior investments from Lux Capital, Nomic is poised for expansion of its proteomics platform, offering opportunities for strategic partnerships and investment in advanced biological data solutions.

Strategic Collaborations Partnerships with research institutions like the Broad Institute and launching large-scale datasets enhance Nomic’s credibility and may open doors for collaboration with organizations needing high-volume, high-quality proteomic data for research and clinical applications.

Market Expansion Operational in both Montreal and Boston with expanding offerings, Nomic serves a growing market of biotech companies and research institutions, presenting sales opportunities for integrated proteomics services and custom data solutions tailored to client needs.

Technological Edge Nomic’s integration of advanced tech stacks—including MATLAB, Cloudflare, and Agilent—is attractive to technology-driven firms seeking innovative solutions, creating sales prospects for partnering on tech-enabled biotech research and platform integrations.